دورية أكاديمية
أعرض في EDS

Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?

التفاصيل البيبلوغرافية
العنوان: Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
المؤلفون: Girardi DM; Department of Oncology, Hospital Sírio-Libanes, SGAS 613-conjunto E lote 95-Asa Sul, Brasília, DF, 70200-001, Brazil. danielmgirardi@gmail.com., Faria LDBB; Department of Oncology, Hospital Sírio-Libanes, SGAS 613-conjunto E lote 95-Asa Sul, Brasília, DF, 70200-001, Brazil., Teixeira MC; Department of Oncology, Hospital Sírio-Libanes, SGAS 613-conjunto E lote 95-Asa Sul, Brasília, DF, 70200-001, Brazil., Costa FP; Department of Oncology, Hospital Sírio-Libanes, SGAS 613-conjunto E lote 95-Asa Sul, Brasília, DF, 70200-001, Brazil., Hoff PMG; Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil., Fernandes GS; Department of Oncology, Hospital Sírio-Libanes, SGAS 613-conjunto E lote 95-Asa Sul, Brasília, DF, 70200-001, Brazil.
المصدر: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2019 Dec; Vol. 50 (4), pp. 860-866.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Science+Business Media Country of Publication: United States NLM ID: 101479627 Publication Model: Print Cited Medium: Internet ISSN: 1941-6636 (Electronic) NLM ISO Abbreviation: J Gastrointest Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2010- : New York : Springer Science+Business Media
Original Publication: New York, NY : Humana Press
مواضيع طبية MeSH: Adenocarcinoma/*drug therapy , Antineoplastic Combined Chemotherapy Protocols/*pharmacology , Deoxycytidine/*analogs & derivatives , Pancreatic Neoplasms/*drug therapy, Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Brazil/epidemiology ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Disease Progression ; Drug Resistance, Neoplasm ; Electronic Health Records/statistics & numerical data ; Female ; Fluorouracil/pharmacology ; Fluorouracil/therapeutic use ; Follow-Up Studies ; Humans ; Irinotecan/pharmacology ; Irinotecan/therapeutic use ; Kaplan-Meier Estimate ; Leucovorin/pharmacology ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Oxaliplatin/pharmacology ; Oxaliplatin/therapeutic use ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/pathology ; Progression-Free Survival ; Quality of Life ; Retrospective Studies ; Gemcitabine
مستخلص: Purpose: Advanced pancreatic adenocarcinoma (PA) is an aggressive disease that has poor prognosis and frequently interferes with patient's quality of life. There has been progress in first-line regimens; however, there is no standard second-line regimen. The aim of this study is to analyze second-line gemcitabine after first-line fluorouracil (FU) + leucovorin (LV) + irinotecan + oxaliplatin (FOLFIRINOX) regimen.
Methods: This study included consecutive patients with advanced PA treated at Hospital Sirio-Libanês from 2011 to 2016. The patients received FOLFIRINOX as first-line treatment and upon progression, received gemcitabine alone. Survival analysis was performed using the Kaplan-Meier method.
Results: A total of 54 patients were evaluated. Most patients were male (61.1%) and most had an ECOG performance status of 0 or 1 prior to the beginning of second-line treatment (66.6%). The mean number of gemcitabine cycles was 3.4. Most patients had disease progression as the best response to treatment (75.9%), 11.1% had stable disease, and 9.3% experienced a partial response. The median progression-free survival was 1.7 months, and the median overall survival was 6.8 months.
Conclusions: Gemcitabine alone did not show meaningful clinical benefit as second-line treatment after FOLFIRINOX.
References: Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Br J Cancer. 2015 Sep 29;113(7):989-95. (PMID: 26372701)
J Clin Oncol. 2016 Nov 10;34(32):3914-3920. (PMID: 27621395)
Exp Hematol Oncol. 2015 Oct 07;4:29. (PMID: 26451276)
J Gastrointest Oncol. 2015 Oct;6(5):511-5. (PMID: 26487945)
N Engl J Med. 2011 May 12;364(19):1817-25. (PMID: 21561347)
Medicine (Baltimore). 2017 Apr;96(16):e6544. (PMID: 28422841)
Oncol Lett. 2017 Jun;13(6):4917-4924. (PMID: 28599496)
BMC Cancer. 2017 Mar 29;17(1):229. (PMID: 28356064)
Lancet. 2016 Feb 6;387(10018):545-557. (PMID: 26615328)
J Clin Oncol. 2014 Aug 10;32(23):2423-9. (PMID: 24982456)
Dig Liver Dis. 2017 Jun;49(6):692-696. (PMID: 28256401)
Rev Recent Clin Trials. 2015;10(2):142-5. (PMID: 25881637)
J Clin Oncol. 1997 Jun;15(6):2403-13. (PMID: 9196156)
Cochrane Database Syst Rev. 2009 Oct 07;(4):CD002093. (PMID: 19821291)
J Gastrointest Oncol. 2017 Jun;8(3):556-565. (PMID: 28736642)
N Engl J Med. 2013 Oct 31;369(18):1691-703. (PMID: 24131140)
فهرسة مساهمة: Keywords: FOLFIRINOX; Gemcitabine; Pancreatic; Second-line treatment
المشرفين على المادة: 0 (folfirinox)
04ZR38536J (Oxaliplatin)
0W860991D6 (Deoxycytidine)
7673326042 (Irinotecan)
Q573I9DVLP (Leucovorin)
U3P01618RT (Fluorouracil)
0 (Gemcitabine)
تواريخ الأحداث: Date Created: 20180904 Date Completed: 20200505 Latest Revision: 20221207
رمز التحديث: 20240628
DOI: 10.1007/s12029-018-0166-4
PMID: 30175393
قاعدة البيانات: MEDLINE
الوصف
تدمد:1941-6636
DOI:10.1007/s12029-018-0166-4